ADA: Insulet delivers first outpatient data for its wearable, closed-loop insulin pump

Insulet Omnipod insulin pump
An upcoming wearable insulin pump houses the algorithm itself and communicates directly with a Dexcom continuous glucose monitor, allowing the delivery system to perform without being tethered to a smartphone or other device. (Insulet)

Insulet delivered the first outpatient data and at-home evaluations of its upcoming Omnipod 5—the tubeless, smartphone-controlled, wearable insulin pump formerly known as the Omnipod Horizon.

The waterproof delivery system, which attaches to the skin of a person’s back, is designed to communicate directly with a Dexcom continuous glucose monitor. The device manages the background insulin algorithm itself and can operate in a closed loop on its own while a smartphone app is used to deliver boluses.

Early data on its use by adults, adolescents and children with Type 1 diabetes were presented virtually at the annual Scientific Sessions of the American Diabetes Association. 

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

The study followed participants over a number of weeks spanning last year’s winter holidays—a time when maintaining a healthy glucose range can be especially difficult for some, according to the study’s presenter, Bruce Buckingham, a professor emeritus in pediatrics, endocrinology and diabetes at Stanford University.

Compared to standard therapy, the Omnipod system helped improve adult participants’ time in a healthy blood sugar range—from 65.5% up to 73.8%—over a four- to nine-week period where they were able to set their own glucose targets based on meals and activity, including overnight. Among children, that time in range was increased from 51% to 70.1%.

RELATED: Insulet will connect Abbott, Dexcom CGMs with its digital, wearable insulin pump

There were no serious adverse events, including no episodes of ketoacidosis or severe episodes of low blood sugar, according to the study.

An additional study of the Omnipod 5 was paused earlier this year after Insulet caught a software glitch that could have caused the system to use incorrect blood glucose values in rare instances.

No adverse events had been reported due to the issue at the time, according to the company, which said the study was about halfway complete when it was paused. 

The study recently resumed earlier this month following a software update. The delay pushed back plans for a commercial launch to the first half of 2021 instead of the second half of this year.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.